MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • All Meetings
    • 2026 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Articles tagged "Lysosomal disorders"

  • 2025 International Congress

    Screening for GBA1 p.K198E PD-Risk Variant in Latin America

    J. Ramchandra, E. Waldo, L. Santiago, TP. Leal, T. Lopez-Gonzalez, M. Inca Martinez, C. Velez-Pardo, D. Pineda, M. Jimenez-Del-Rio, F. Lopera, S. Moreno, O. Buritica, J. Orozco, B. Muñoz Ospina, M. Camacho, G. Arboleda, H. Arboleda, O. Bernal, CE. Arboleda-Bustos, IF. Mata (Cleveland, USA)

    Objective: We aimed to assess the distribution of the GBA1 p.K198E variant, linked to Gaucher’s disease (GD) and increased Parkinson’s disease (PD) risk, across Latin…
  • 2025 International Congress

    CAP-003, a CNS-targeted IV-delivered AAV Gene Therapy Developed for Patients with Parkinson’s Disease associated with GBA1 Mutations

    K. Mcdowell, R. Ressler, M. Flynn, B. Wheeler, L. Grigoryeva, A. Armendariz, H. Acharya, P. Denis, J. Granados, P. Tchourilov, C. Pedeferri, M. Brandabur, S. Tole, N. Goeden, N. Flytzanis (Thousand Oaks, USA)

    Objective: CAP-003 is a next-generation gene therapy candidate, comprising a novel brain-tropic capsid paired with hGBA1 cargo, that was developed for administration as a single…
  • 2025 International Congress

    Neurological manifestations and genotypes of Gaucher disease type 3: MDSGene systematic review

    S. Schaake, T. Usnich, J. Boehm, N. Steffen, N. Schell, C. Krüger, T. Gül-Demirkale, N. Bahr, T. Kleinz, H. Madoev, B. Laabs, Z. Gan-Or, R. Alcalay, C. Marras, K. Lohmann, C. Klein, M. Rossi (Luebeck, Germany)

    Objective: To characterize the spectrum of neurological manifestations of Gaucher disease type 3 (GD3) and identify the most common GBA1 variants. Background: Gaucher disease is…
  • 2025 International Congress

    Modifiers of Parkinson’s disease associated with mutations in the GBA1 gene based on transcriptome data validation

    A. Bezrukova, K. Basharova, I. Miliukhina, S. Pchelina, T. Usenko (Gatchina, Russian Federation)

    Objective: To identify modifiers of Parkinson's disease (PD) among carriers of mutations in the GBA1 gene based on transcriptome data validation analysis by the assessing…
  • 2025 International Congress

    Oligodendrocyte-specific mRNA therapy with lipid nanoparticles

    M. Sawamura, K. Tachikawa, R. Hikawa, H. Yamakado, R. Takahashi, S. Matsuzawa (San Diego, USA)

    Objective: To develop lipid nanoparticles with high efficiency and specificity to introduce mRNA into oligodendrocytes. To denmonstrate the potential therapy of Krabbe disease as one…
  • 2025 International Congress

    G-Can, the GBA1 Canada Initiative

    L. Chebon, P. Halder, E. Fon, T. Durcan, M. Parent, N. Dupre, M. Sharp, R. Postuma, G. Armstrong, A. Milnerwood, A. Dagher, J. Raamsdonk, J. Trempe, T. Goldsmith, X. Chen, N. Aprahamian, Z. You, M. Nicoleau, E. Deneault, A. Bayne, C. Laflamme, P. Mcpherson, M. Pandolfo, G. Rouleau, Z. Gan-Or (Québec, Canada)

    Objective: G-Can, the GBA1 Canada Initiative, is an open-science platform which aims to advance GBA1 research and develop treatments for GBA1 mutation-related Parkinson's disease (PD).…
  • 2025 International Congress

    Investigating the cellular consequences of the G2385R LRRK2 variant

    P. Lewis, S. Herbst (London, United Kingdom)

    Objective: The objective of this study is to characterise the biochemical and cellular impact of the G2385R coding variant in LRRK2, a risk variant for…
  • 2025 International Congress

    CSM-101 is a Small Molecule Agonist of TRPML1 for Parkinson’s-Related Disorders

    L. Murphy, J. Fortanet, D. Baird, T. Lehmberg, K. Skerry, M. Broadus (Boston, USA)

    Objective: (i) To develop a brain-penetrant small molecule agonist for the lysosomal TRPML1 channel and, (ii) Perform preclinical studies supporting development in Parkinson’s-related disorders. Background:…
  • 2025 International Congress

    VQ-101, a CNS-Penetrant Small Molecule Allosteric Activator of Glucocerebrosidase (GCase), Demonstrates Favorable Tolerability and Sustained Activation of Lysosomal GCase in Individuals with Parkinson’s Disease

    M. Facheris, D. Ysselstein, J. van Dervalk, E. Thijssen, L. Pagan, G. Valstar, C. Schotborgh, P. Kremer, M. Hagey, J. Cederbaum, J. Sullivan, K. Hunt, O. Siddiqui (Chicago, USA)

    Objective: To assess the safety, tolerability, pharmacokinetics and pharmacodynamics of VQ-101 in healthy volunteers (HVs), and individuals with Parkinson’s disease (PD) with and without GBA1…
  • 2025 International Congress

    The sphingolipid Lyso-Gb3, a biomarker for the lysosomal storage disorder Fabry Disease, is significantly elevated in blood from patients with Parkinson’s Disease

    C. Beetz, C. Cozma, M. Iurascu, S. Fischer, S. Oppermann, K. Kandaswamy, P. Bauer (Rostock, Germany)

    Objective: To better understand lysosomal dysfunction in Parkinson’s Disease. Background: Lysosomal dysfunction and α-synuclein accumulation play central roles in Parkinson’s Disease. They are interconnected by…
  • « Previous Page
  • 1
  • 2
  • 3
  • 4
  • 5
  • …
  • 10
  • Next Page »

Related Sites

International Parkinson and Movement Disorder Society

The Society that manages the annual International Congress »

International Congress

The official website for the International Congress of Parkinson’s and Movement Disorders® »

  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2026 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley